Compass Pathways Q4 2023 net loss $32.5M; COMP005 data delayed to Q4 2024

COMPASS Pathways plc

2023-FY EPS reported -$2.32

Net loss for FY2023 $118.5M ($2.32/sh) vs $91.5M ($2.16/sh) in 2022.
Cash $220.2M at Dec 31, 2023; raised additional $31.4M net in Q1 2024.
COMP005 phase 3 top-line data delayed to Q4 2024; COMP006 still on track for mid-2025.
Teri Loxam appointed CFO effective March 1, 2024.
FY2024 net cash used in operations expected $110-130M; runway into late 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

COMPASS Pathways plc reported fourth quarter and year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was $118.5 million, or $2.32 loss per share, EPS $2.32 loss per share.

Period: fourth quarter and year ended December 31, 2023
Net income: Net loss for the year ended December 31, 2023, was $118.5 million, or $2.32 loss per share
EPS: $2.32 loss per share
Result: reported results

Exact text from the filing

Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter 2023 and provided an update on recent progress across its business.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

COMPASS Pathways plc filing history →

Source: SEC EDGAR

accession 0001628280-24-007788

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.